Every cell in our body contains the same DNA sequence, yet heart cells are very different from liver cells. This is due to thousands of differences in how these cells generate (or transcribe) RNA. With our growing RNA dataset, Arpeggio is learning connections between RNA expression, cell type, and disease.Learn More
Many common diseases such as cancer and neurodegeneration are driven not just by dysfunction of a single gene but by the misregulation of hundreds or thousands of RNAs. At Arpeggio, we compare healthy and diseased cell states to identify RNA signatures that define disease. By identifying these RNAs we search for drugs that specifically reverse disease signatures.Learn More
Drugs can have massive effects on a cell's RNA, but modulation of just a few important RNAs can treat or cure a disease. Identifying drugs that can precisely modulate these RNAs is a major goal of pharmaceutical drug development and our mission at Arpeggio.
Arpeggio utilizes a unique technology called nascent RNA sequencing to measure RNAs directly affected by a compound treatment. This allows us to identify the primary effect of a drug on a cell and very quickly hone in on its mechanism. With new advances in next-generation sequencing and robotics, we're scaling our nascent RNA sequencing platform to test tens of thousands of compounds at a time.
Navigating complex biology requires input from many different assays. Our team includes world experts in functional genomics assay development and optimization.
Have questions? Interested in partnering with Arpeggio? Let us know.